COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes.
Adrianne L JennerRosemary A AogoSofia AlfonsoVivienne CroweXiaoyan DengAmanda P SmithPenelope A MorelCourtney L DavisAmber Marie SmithMorgan CraigPublished in: PLoS pathogens (2021)
To understand the diversity of immune responses to SARS-CoV-2 and distinguish features that predispose individuals to severe COVID-19, we developed a mechanistic, within-host mathematical model and virtual patient cohort. Our results suggest that virtual patients with low production rates of infected cell derived IFN subsequently experienced highly inflammatory disease phenotypes, compared to those with early and robust IFN responses. In these in silico patients, the maximum concentration of IL-6 was also a major predictor of CD8+ T cell depletion. Our analyses predicted that individuals with severe COVID-19 also have accelerated monocyte-to-macrophage differentiation mediated by increased IL-6 and reduced type I IFN signalling. Together, these findings suggest biomarkers driving the development of severe COVID-19 and support early interventions aimed at reducing inflammation.
Keyphrases
- sars cov
- coronavirus disease
- immune response
- dendritic cells
- respiratory syndrome coronavirus
- early onset
- end stage renal disease
- oxidative stress
- case report
- ejection fraction
- chronic kidney disease
- adipose tissue
- prognostic factors
- endothelial cells
- molecular docking
- metabolic syndrome
- weight loss
- glycemic control